VRNA250117C45000
- 1.60
- -0.45-21.95%
Verona Pharma Newsroom
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
Analysts Expect Breakeven For Verona Pharma Plc (NASDAQ:VRNA) Before Long
Roth MKM Initiates Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $68
Verona Pharma's Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth
Verona Pharma Is Maintained at Overweight by Wells Fargo
Verona Pharma Analyst Ratings
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $57
Wells Fargo Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $74
Wells Fargo Sticks to Their Buy Rating for Verona Pharma (VRNA)
BTIG Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $77
Sector Update: Health Care Stocks Advance Late Afternoon
Verona Pharma Shares Are Trading Higher Following Q4 Financial Results.
Verona Pharma to Report $36 Million in Q4 Net Product Revenue
Truist Securities Raises Price Target on Verona Pharma to $57 From $44, Maintains Buy Rating
Verona Posts Early Sales Figures for Q4 and 2024
Verona Pharma Sees 4Q Product Sales of $36M >VRNA
Press Release: Verona Pharma Reports Strong Ohtuvayre(TM) Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
Verona Pharma (NASDAQ:VRNA) Shareholder Returns Have Been Incredible, Earning 755% in 5 Years
Five Reasons Why UBS Is Overweight the UK
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for Week